Petrelintide
ZP8396 Zealand
An investigational once-weekly amylin analog, and the first amylin tested on its own for obesity rather than alongside a GLP-1. It is not approved for any use.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Advanced
What Petrelintide is used for
- Amylin monotherapy — a different appetite pathway from the GLP-1 class
- Up to 10.7% mean weight loss at 42 weeks vs 1.7% on placebo (ZUPREME-1, 493 participants)
- Placebo-like tolerability reported: no vomiting and no GI discontinuations at the maximally effective dose
How it's typically used
Trial range: once-weekly subcutaneous dosing titrated per study protocol. Not approved — trial participation is the only route.
What to watch for
- Investigational; Phase 2 complete, Phase 3 decision pending, not approved anywhere
- Weight loss at 42 weeks is below what the top incretins report — the argued trade is tolerability, not magnitude
- Not obtainable outside a clinical trial
- ZUPREME-2, the type 2 diabetes study, has not reported yet
Common questions
- How is Petrelintide taken?
- Petrelintide is typically administered by the subcutaneous route. Trial range: once-weekly subcutaneous dosing titrated per study protocol. Not approved — trial participation is the only route.
- What are the risks of Petrelintide?
- Investigational; Phase 2 complete, Phase 3 decision pending, not approved anywhere Weight loss at 42 weeks is below what the top incretins report — the argued trade is tolerability, not magnitude Not obtainable outside a clinical trial ZUPREME-2, the type 2 diabetes study, has not reported yet
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.